ibusinesslines.com February 18, 2018

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Downgraded by Morgan Stanley

17 July 2017, 08:37 | Kelvin Horton

On 07/13/2017 close, Ocular Therapeutix, Inc. Morgan Stanley lowered shares of Ocular Therapeutix from an "overweight" rating to an "equal weight" rating and set a $16.00 price objective for the company.in a research note on Friday, June 23rd. American International Group Inc. now owns 11,138 shares of the biopharmaceutical company's stock worth $103,000 after buying an additional 844 shares during the last quarter.

A number of brokerages have recently weighed in on OCUL. The other 3, though not evenly; between analysts who think you should buy Ocular Therapeutix, Inc. versus those who think you should sell it. According to Thomson Reuters, sell-side analysts are forecasting a harmony target price of $27.00 on company shares. The firm has "Overweight" rating by Cantor Fitzgerald given on Friday, February 10. They now have a Dollars 21 price target on the stock. The stock experienced -4.88% slump, arriving at $6.33 on Jul. 14, 2017. In contrast, the average volume was 1.37 million shares. The stock's current distance from 20-Day Simple Moving Average (SMA20) is -30.31% where SMA50 and SMA200 are -32.26% and -22% respectively. Ocular Therapeutix has a one year low of $4.04 and a one year high of $11.91. The stock's market capitalization is $178.52 million.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings results on Friday, May 5th. The company maintains price to book ratio of 2.15 vs.an industry average at 1.27. It has a return on equity (ROE) of -80.20%. The firm had revenue of $0.48 million for the quarter, compared to the consensus estimate of $0.51 million. (OCUL) is -0.58 while the analysts predicted the EPS of the stock to be -0.48 suggesting the company fell short of the analysts' expectations. On average, equities analysts expect that Ocular Therapeutix will post ($2.25) EPS for the current fiscal year. The correct version of this article can be viewed at https://www.com-unik.info/2017/07/17/fy2017-eps-estimates-for-ocular-therapeutix-inc-lifted-by-cantor-fitzgerald-nasdaqocul.html. Cantor Fitzgerald now has a "Overweight" rating and a $21.00 target price on the stock. If you are reading this news story on another website, it was stolen and reposted in violation of global trademark & copyright laws. About shares traded. Ocular Therapeutix Inc (NASDAQ:OCUL) has declined 9.50% since July 17, 2016 and is downtrending.

Institutional investors have recently added to or reduced their stakes in the company.

ILLEGAL ACTIVITY WARNING: "49,024 Shares in Ocular Therapeutix, Inc".

A stock rating usually tells investors how well a stock's market value relates to what analysts think is a fair value for the stock, based on an independent evaluation of the company. Berson & Corrado Investment Advisors LLC increased its stake in Ocular Therapeutix by 5.8% in the first quarter. Columbus Circle Investors boosted its stake in Ocular Therapeutix by 131.4% in the first quarter. Deltec Asset Management LLC now owns 399,200 shares of the biopharmaceutical company's stock worth $3,705,000 after buying an additional 284,200 shares during the period. Finally, Trexquant Investment LP bought a new position in shares of Ocular Therapeutix during the fourth quarter valued at about $181,000.

Institutional investors now hold around $122 million or 63.9% in OCUL stock.

Taking a look back at some historical performance numbers for Ocular Therapeutix, Inc. The Firm is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology.

Other News

Trending Now

Trump administration asks Supreme Court to clarify travel ban ruling
But grandparents, grandchildren, aunts, uncles, nieces, nephews, cousins, brothers-in-law and sisters-in-law are excluded. The two filings overlap, and the appeals court could defer action until it sees what the Supreme Court does.

Chelsea striker Costa parties in Atletico shirt and mocks Conte
The Blues' top scorer will be unable to play until January as Atletico are now under a transfer embargo. Costa, now twenty-eight-years-old, scored twenty goals in thirty-five league appearances last season.

Cubs Waste Big Lead, Hang On To Beat Orioles 9-8
The Chicago Cubs will look to complete the sweep of the O's after a 10-3 victory over Baltimore in game two on Saturday. Danny Valencia and Kyle Seager also hit home runs for the Mariners, who extended their winning streak to four.

DHS Approves 15000 Additional Temporary Worker Visas
To receive the visas, businesses must attest they would suffer irreparable harm if they can not bring in those workers. The administration insisted the visa boost is not incompatible with its "America first" pledge.

Thomas Lemar has the right profile for Arsenal, says Robert Pires
The Daily Star claim Lemar has set his sights on a move to the Emirates and can not wait to work under Arsene Wenger. The Daily Star claims the French global is afraid Monaco might actually block his path to the Premier League.

Increasing time to deposit old notes defeats demonetisation: Centre to SC
However, the government said that adequate time was provided to exchange or deposit the old currency notes. The 50-day deadline to deposit the old Rs 500 and 1,000 notes in banks comes to an end on December 30.

South Korea proposes inter-Korean military talks to thaw cross-border tension
Yet even if it does, the prospects of the negotiations remain shaky given the gap in positions between the sides, observers say. In recent years, Seoul and its ally Washington have expressed deep concerns about the North's missile and nuclear programs.